The new anti-Covid oral drug developed by the DRDO
will help hospitalized patients and reduce their supplemental
oxygen dependence. The drug 2-deoxy-D-glucose (2-DG) has
been developed by the Institute of Nuclear Medicine and
Allied Sciences (INMAS), a leading laboratory of Defence Research and
Development Organization (DRDO), in collaboration with Dr Reddy’s
Laboratories (DRL) in Hyderabad. The drug, which comes in powder
form in a sachet and is taken orally by dissolving it in water, was approved
by the Drugs Controller General of India (DCGI) for emergency use as
an adjunct therapy. News18, in an exclusive with the DRDO Project
Director and Scientist of 2-DG, Dr Sudhir Chandana, explains how
anti-Covid-19 therapeutic application of the drug will work on patients.
